A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems.

Trial Profile

A Randomized, Multicenter, Parallel Group, Dose-Ranging Study to Evaluate the Safety and Tolerability of SPN-810 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Persistent Serious Conduct Problems.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jul 2012

At a glance

  • Drugs Molindone (Primary)
  • Indications Attention-deficit hyperactivity disorder; Behavioural disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Apr 2012 Results published in the Journal of Child and Adolescent Psychopharmacology.
    • 28 Jan 2010 The primary endpoint of safety and tolerability was met according to a Supernus media release.
    • 28 Jan 2010 A Supernus media release presented positive results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top